Last reviewed · How we verify
NCT02430675: IRE
Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms
NA trial testing Irreversible electroporation (IRE) in Laryngeal Neoplasms in 30 participants. Completed in 1 January 2021.
1 December 2020
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 January 2015 |
| Primary completion | 1 December 2020 |
| Estimated completion | 1 January 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Irreversible electroporation (IRE)
- NanoKnife
Conditions studied
- Laryngeal Neoplasms — all drugs for Laryngeal Neoplasms →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Eligibility, any sex, with Laryngeal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Laryngeal Neoplasms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02430675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Irreversible electroporation (IRE)
Trials testing the same drug.
- NCT05435053 — Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer · Phase 2 · terminated
- NCT02430597 — Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms · NA · completed
- NCT02335112 — Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms · NA · completed
- NCT02430662 — Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms · NA · completed
- NCT02430688 — Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms · NA · completed
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02430675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 5 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02430675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing